Abstract
A new synthetic route to ring-constrained (N)-methanocarba nucleosides and nucleotides is presented. Ring closure of a diene intermediate using Grubbs catalyst provides a new avenue for the preparation of the cyclopentenone derivative 6, which is a versatile intermediate for various carbocycles. The product was almost as potent an inhibitor of es-mediated nucleoside transport as the parent compound, inhibiting initial rates of uptake of uridine into cultured CCRF-CEM cells by 50% at approximately 30–50 nM.
Graphical Abstract

Modulation of adenosine receptors (ARs) and nucleotide (P2) receptors by adenosine derivatives acting as selective agonists and antagonists has the potential for the treatment of wide range of diseases, including those of the cardiovascular, inflammatory, and central nervous systems.1 A methanocarba approach to conformationally constrain the sugar ring in nucleosides and nucleotides was introduced by Marquez and co-workers.2 Using this approach, a pseudosugar moiety, based on a bicyclo[3.1.0]hexane template, was fixed in either a Northern ((N), 2′-exo) or Southern ((S), 2′-endo) conformation, according to the pseudorotational cycle. For studies of the ribose ring conformation of nucleosides and nucleotides binding to G protein-coupled receptors (GPCRs), we designed methanocarba analogues. Novel ligands for both ARs3 and P24 receptors, in which the pseudoribose moiety adopted a (N)-conformation, provided favorable receptor affinity and/or selectivity compared to their corresponding (S)-conformers. In binding assays at A1, A2A, and A3ARs, (N)-methanocarba-adenosine had a higher affinity than the (S)-analogue, particularly at the human A3AR, with a (N)/(S)-affinity ratio of 150. (N)-Methanocarba analogues containing various N6-substituents, in which the parent compounds were potent agonists at either A1 (e.g., cyclopentyl) or A3ARs (e.g., 3-iodobenzyl), were found to retain the potency and selectivity in radioligand binding assays.3 Thus, at least three ARs favored the ribose (N)-conformation.
In this paper we report the efficient synthesis of a (N)-methanocarba S-(4-nitrobenzyl)thioinosine (NBTI) derivative5 as a potential inhibitor of the adenosine uptake carrier, employing a straightforward synthetic strategy. Our approach to the preparation of the key intermediate, 6 (Scheme 1), is centered on a ring closing metathesis (RCM) reaction6 to provide rapid entry into functionalized and enantiomerically pure carbocycles. Starting from the appropriately protected alcohol 1, which is readily accessible from d-(+)-ribono γ-lactone in four steps,7 the required diene, 3, was constructed in good yield. After oxidation of the tert-butyldiphenylsilyl (TBDPS)-protected alcohol, 1, in Swern conditions, a Wittig reaction was followed by the removal of the TBDPS group using n-tetrabutylammonium fluoride to provide the olefinic alcohol, 2. The necessary precursor, i.e., diene 3, was then prepared as a diastereomeric mixture by Swern oxidation followed by treatment with 1 M vinylmagnesium bromide in THF at −78 °C. The critical olefin metathesis reaction was accomplished in 80–90% yield by exposure of a dichloromethane solution of diene 3 to 0.2 equiv of the Grubbs catalyst, 4,6 for 2 h to give a diastereomeric mixture of cyclopentenols, 5. The ratio of the alcohols 3 was determined at compound 5 after ring closure reaction (7.3:1, 1R-isomer as major). Allylic oxidation of the alcohol 5 using activated MnO2 furnished the corresponding ketone, 6, in 80% yield. The physical and spectroscopic properties of the synthesized compound, 6, including optical rotation ([α]20D = −7.2, c = 1.08, CHCl3), matched with those reported.11b To prepare the ring-constrained bicyclic compound 7, compound 6 was treated with NaBH4, along with CeCl3, followed by Simmon–Smith cyclopropanation, according to the reported procedure.8
Scheme 1a.

a (a) (COCl)2, DMSO, THF, −78 °C, then TEA, rt. (b) PPh3CH3Br, n-BuLi, THF. (c) TBAF, CH3CN. (d) (COCl)2, DMSO, THF, −78 °C, then TEA, rt. (e) Vinylmagnesium bromide, THF, −78 °C. (f) 4, CH2Cl2. (g) MnO2, CHCl3.
As shown in Scheme 2, the ribose-like moiety 7 was coupled to 6-chloropurine using Mitsunobu conditions to give the fully protected nucleoside 8,8 which was then converted to 9 by the treatment with 1 M BCl3 in CH2Cl2 followed by reforming the acetonide at the 1,2-diol. The target compound, 11,9 was obtained from 9 by reflux with 4-nitrobenzylthiol, 10,10 and sodium methoxide followed by cleavage of the isopropylidene group by trifluoroacetic acid in wet methanol at 60 °C.
Scheme 2a.

a (a) 6-Cl-purine, DEAD, Ph3P, THF. (b) (i) BCl3, CH2Cl2, −78 °C, (ii) DMP, acetone, pTsOH. (c) (i) 10, NaOMe, MeOH, reflux, (ii) TFA, wet MeOH, 60 °C.
Previous syntheses of (N)-methanocarba nucleosides that rely on compound 6 as a starting material have suffered from the lengthy and low-yielding routes to this key intermediate.11,12 In particular, the route of Johnson and co-workers11a to intermediate 6 required a cyclopentenone intermediate obtained in low yield and featured a stannyl intermediate for introducing the 5′-carbon. The route of Marquez and co-workers11b was dependent on a low yield cyclization of a diketophosphonate intermediate, which was complicated by racemization. By our method, it was possible to obtain 1 g of 6 starting from 5 g of d-(+)-ribono γ-lactone (10.8% overall yield).
The newly synthesized (N)-methanocarba-NBTI derivative, 11, was examined for its ability to inhibit nucleoside transport by the equilibrative transporters (es, ei)13 by measuring initial rates of uptake of 10 μM 3H-uridine in the presence or absence of graded concentrations of either 11 or NBTI (S-(4-nitrobenzyl)thioinosine)5 by cultured human cells that possess only es (CCRF-CEM)14,15 or both es and ei (HeLa)16 transporters. The IC50 values (concentrations that inhibited transport rates by 50%) calculated from concentration-effect relationships for inhibition of es-mediated uridine transport in CCRF-CEM cells by 11 and NBTI were, respectively, 30–50 and 1–5 nM. Compound 11, like NBTI, had no effect on ei-mediated transport of uridine by HeLa cells at concentrations ≤1.0 μM.
Thus, the introduction of a conformationally constrained ribose equivalent satisfied the conformational requirements of the transport-inhibitory site. Compound 11 bound with high affinity, only slightly less than that of NBTI, thereby demonstrating that it, like NBTI, is a useful probe for analysis of the es transporter. Further work will be required to determine if other properties of the (N)-methanocarba analogue give it advantages over NBTI as a potential modulator of transport. Compound 11 also bound to the human A3AR3 with a Ki of 1.97 ± 0.10 μM.
In summary, we developed an efficient synthetic methodology for the cyclopentenone derivative 6, utilizing RCM reaction as a key step, leading to a variety of carbocyclic compounds. During the writing of this paper, Al-Abed and co-workers17 reported the synthesis of carba-d-arabinose using a similar strategy, including olefin metathesis, starting from a carbohydrate source. In that study, the more reactive and air-sensitive Schrock’s catalyst was used.
Supplementary Material
Acknowledgment.
We thank Dr. Y. Choi, Dr. X.-D. Ji, and Dr. V. E. Marquez for helpful discussions.
Footnotes
Supporting Information Available: Experimental procedures and spectroscopic data for compounds 2–3, 5, 6, 8, 9, and 11. This material is available free of charge via the Internet at http://pubs.acs.org.
References
- (1).Fredholm BB; Abbracchio MP; Burnstock G; Dubyak GR; Harden TK; Jacobson KA; Schwabe U; Williams M Trends Pharmacol. Sci. 1997, 18, 79. [DOI] [PMC free article] [PubMed] [Google Scholar]; Jacobson KA; Knutsen LJS P1 and P2 purine and pyrimidine receptors. In Handbook of Experimental Pharmacology; Abbracchio MP, Williams M Eds.; Springer: Berlin, 2001; in press. [Google Scholar]
- (2).(a) Rodriguez JB; Marquez VE; Nicklaus MC; Mitsuya H; Barch JJ Jr. J. Med. Chem. 1994, 37, 3389. [DOI] [PubMed] [Google Scholar]; (b) Marquez VE; Siddiqui MA; Ezzitouni A; Russ P; Wang J; Wagner RW; Matteucci MD J. Med. Chem. 1996, 39, 3739. [DOI] [PubMed] [Google Scholar]; (c) Marquez VE; Ezzitouni A; Russ P; Siddiqui MA; Ford H Jr.; Feldman RJ; Mitsuya H; George C; Barch JJ Jr. J. Am. Chem. Soc. 1998, 120, 2780. [Google Scholar]; (d) Moon HR; Kim HO; Chun MW; Jeong LS; Marquez VE J. Org. Chem. 1999, 63, 4733. [DOI] [PubMed] [Google Scholar]
- (3).Jacobson KA; Ji X-D; Li AH; Melman N; Siddiqui MA; Shin KJ; Marquez VE; Ravi RG J. Med. Chem. 2000, 43, 2196. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (4).Nandanan E; Jang SY; Moro S; Kim HO; Siddiqui MA; Russ P; Marquez VE; Busson R; Herdewijn P; Harden TK; Boyer JL; Jacobson KA J. Med. Chem. 2000, 43, 829. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (5).(a) Crawford CR; Ng CYC; Noel LD; Belt JA J. Biol. Chem. 1990, 265, 9732. [PubMed] [Google Scholar]; (b) Dagnino L; Bennett LL Jr.; Paterson ARP J. Biol. Chem. 1991, 266, 6308. [PubMed] [Google Scholar]; (c) Baldwin SA; Mackey JR; Cass CE; Young JD Mol. Med. Today 1999, 5, 216. [DOI] [PubMed] [Google Scholar]
- (6).(a) Nguyen ST; Johnson LK; Grubbs RH; Ziller JW J. Am. Chem. Soc. 1992, 114, 3974. [Google Scholar]; (b) Grubbs RH; Miller SJ Acc. Chem. Res. 1995, 28, 446. [Google Scholar]; (c) Schmalz H-G Angew. Chem., Int. Ed. Engl. 1995, 34, 1833. [Google Scholar]; (d) Grubbs RH; Chang S Tetrahedron 1998, 54, 4413. [Google Scholar]
- (7).Ohira S; Sawamoto T; Yamato M Tetrahedron Lett. 1995, 36, 1537. [Google Scholar]
- (8).Jeong LS; Marquez VE; Yuan C-S; Borchardt RT Heterocycles 1995, 41, 2651. [Google Scholar]
- (9).1H NMR δ (CD3OD): 8.79 (s, 1H), 8.74 (s, 1H), 8.78, 8.15 (2s, 2H), 7.76, 7.64 (2s, 2H), 4.46–4.99 (m, 3H), 4.87 (s, 1H), 4.72 (s, 2H), 4.24 (m, 1H), 3.89 (m, 1H), 1.56 (m, 1H), 0.93 (m, 1H). HRMS (FAB): calcd 430.1185, found 430.1171.
- (10).Bellas M; Tuleen DL; Field L J. Org. Chem 1967, 32, 2590. [Google Scholar]
- (11).(a) Medich JR; Kunnen KB; Johnson CR Tetrahedron Lett. 1987, 28, 4131. [Google Scholar]; (b) Marquez VE; Lim M-I; Tseng CK-H; Markovac A; Priest MA; Khan MS; Kaskar BJ Org. Chem. 1988, 53, 5709. [DOI] [PubMed] [Google Scholar]
- (12).(a) Altman K-H; Kesselring R; Francotte E; Rihs G Tetrahedron Lett. 1994, 35, 2331. [Google Scholar]; (b) Siddiqui MA; Ford H Jr.; George C; Marquez VE Nucleosides Nucleotides 1996, 15, 235. [DOI] [PubMed] [Google Scholar]
- (13).“es” refers to equilibrative inhibitor-sensitive and “ei” refers to equilibrative inhibitor-insensitive systems.
- (14).Cass CE; King KM; Montano JT; Janowska-Wieczorek A Cancer Res. 1992, 52, 5879. [PubMed] [Google Scholar]
- (15).Crawford CR; Ng CY; Ullman B; Belt JA Biochim. Biophys. Acta 1990, 1024, 289. [DOI] [PubMed] [Google Scholar]
- (16).Boumah CE; Hogue DL; Cass CE Biochem. J. 1992, 288, 987. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (17).Seepersaud M; Al-Abed Y Tetrahedron Lett. 2000, 41, 7801. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
